Osphena Approved by FDA to Treat Dyspareunia

Article

Osphena (ospemifene) has been approved by the FDA to treat dyspareunia. This is the first non-steroidal estrogen available for women with dyspareunia (painful intercourse), a symptom of vulvar and vaginal atrophy (VVA) that is common during menopause.

Osphena (ospemifene), an estrogen agonist/antagonist with tissue selective effects, has been approved by the FDA to treat dyspareunia. This is the first non-steroidal estrogen available for women with dyspareunia (painful intercourse), a symptom of vulvar and vaginal atrophy (VVA) that is common during menopause. 

The results of a multicenter, randomized, double-blind, placebo-controlled trial and subsequent safety extension were published online and ahead of print in the journal Menopause. Researchers found that 60 mg of once-daily oral ospemifene was effective in treating of vulvar and vaginal atrophy in postmenopausal women with dyspareunia.1  The one-year, long-term safety extension study found no clinically significant adverse changes, including no clinically meaningful endometrial findings, no treatment-emergent adverse events of pelvic organ prolapse or venous thromboembolism, and no cases of endometrial hyperplasia or carcinoma.2 In both studies, hot flushes were the most common treatment-related adverse event.
 

References:

1. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause. 2013 Jan 28. [Epub ahead of print].
2. Simon JA, Lin VH, Radovich C, Bachmann GA; The Ospemifene Study Group. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause. 2012 Nov 8. [Epub ahead of print].

Recent Videos
Navigating hormone therapy in high-risk menopause cases | Image Credit: © dhaj7-cepo.com.
Non-hormonal treatments offer relief for genitourinary syndrome of menopause | Image Credit: providers.uthscsa.edu.
Jill Liss, MD, MSCP, FACOG, associate clinical professor, OB/GYN, at the University of Colorado School of Medicine.
Elizabeth Gandee, APRN-CNP, highlights gaps in women's menopause knowledge | Image Credit: wexnermedical.osu.edu
Shayna Mancuso, DO, highlights the real impact of menopause | Image Credit: linkedin.com.
Jennifer Payne, MD, highlights how to help young women with perimenopause symptoms | Image Credit: uvahealth.com/findadoctor.
Dr. Somi Javaid provides advice for sexual health care | Image Credit: hermd.com.
Efficacy found from biopsychosocial approach to women’s sexual health | Image Credit: hermd.com.
Dr. Somi Javaid highlights disparities in sexual health | Image Credit: hermd.com.
Worse menopause symptom burden reported in rural women | Image Credit: uwmedicine.org.
Related Content
© 2025 MJH Life Sciences

All rights reserved.